GLP1R and pancreatic neoplasm: Similarly, a 2023 meta‐analysis with 43 trials found that pancreatitis (OR: 1.24, 0.94–1.64, p = 0.13) and pancreatic cancer (OR: 1.28, 0.87–1.89, p = 0.20) displayed no clear association for GLP‐1 RA usage [20].